about
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.The effectiveness of a self-management occupational therapy intervention on activity performance in individuals with multiple sclerosis-related fatigue: a randomized-controlled trial.Multiple sclerosis in Belgian children: A multicentre retrospective study.Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens.Except for C-C chemokine receptor 7 expression, monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls.Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.Endogenous Pain Facilitation Rather Than Inhibition Differs Between People with Chronic Fatigue Syndrome, Multiple Sclerosis, and Controls: An Observational Study.What is in a name? Comparing diagnostic criteria for chronic fatigue syndrome with or without fibromyalgia.Recovery of peripheral muscle function from fatiguing exercise and daily physical activity level in patients with multiple sclerosis: a case-control study.Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study.Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis.IgLON5-Associated Encephalitis With Atypical Brain Magnetic Resonance Imaging and Cerebrospinal Fluid Changes.Galactosidase Alpha p.A143T Variant Fabry Disease May Result in a Phenotype With Multifocal Microvascular Cerebral Involvement at a Young Age.Into the Moment: Does Mindfulness Affect Biological Pathways in Multiple Sclerosis?Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factorsSubacute onset Hirayama disease with extensive myelopathy on MRI in flexed postureA Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosisErratum to: Subacute onset Hirayama disease with extensive myelopathy on MRI in flexed postureTolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administrationClinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNAFluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialCognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity
P50
Q37597918-DB78CEE8-716C-41C6-964B-6C9F645084B6Q38123575-F82697C9-FC4C-41B4-AD18-C0DF8E941FFBQ38866881-AB162F98-B944-477D-8EA1-C33B83794EDBQ40487276-709D109C-D83F-4D4C-92D6-8685EC198C95Q40516749-997B74F4-BB70-4736-AABA-6BC1111F5A28Q42214016-956E49A2-E920-4225-922E-A92025E1EC05Q42665193-32B09A3E-BE00-4F1D-B9AF-C13FFD923D15Q47366640-932ECF0A-17EC-4ED9-85C8-A5B56EDD5DF7Q48062917-7C97097C-9042-4B94-84F2-5E181865C8B4Q49065370-AE9FBA16-1BDB-4966-BB93-360E7C001206Q52591511-5962C9AB-5986-40D7-80F1-B17CA9FCC9E8Q54211751-644CCE38-99B5-4E8A-8789-B21D7E98807EQ55092778-3D741805-1751-4BA7-9DD3-37BA78E6F4E5Q55197229-5987881D-160D-498F-B9EC-3DEF08E646DAQ55346807-BFDFC030-8AF2-443F-9AA4-28AB5AAFC6FEQ59149657-17B6E9A5-2DC3-48B7-A707-DBBBB6A091FBQ87919969-7BC84D65-217E-4687-816D-3648AA3C350CQ88047177-25759884-89F6-4EF5-B82A-D5C5F86327E6Q88115422-D21356D2-6B3F-4033-A026-12EC67E23E8BQ90000635-D87CDC81-0B30-4C7F-B3C6-C82C08712FF0Q92643875-9152D062-3783-4446-9FC8-2DDDAA511F2AQ92894028-3015C814-EDA7-446F-AE21-0E9E9C483491Q92997339-1602CB83-DBA9-4F14-A0FB-82D9F4E83112
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Barbara Willekens
@en
Barbara Willekens
@nl
type
label
Barbara Willekens
@en
Barbara Willekens
@nl
prefLabel
Barbara Willekens
@en
Barbara Willekens
@nl
P31
P496
0000-0002-5212-8837